The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
The First Clinical Medical College, Lanzhou University, Lanzhou, China.
Orthop Surg. 2023 Sep;15(9):2244-2259. doi: 10.1111/os.13806. Epub 2023 Jul 5.
Osteosarcoma (OS) is a common malignant bone tumor that occurs mostly in children and adolescents. At present, surgery after chemotherapy or postoperative adjuvant chemotherapy is the main treatment plan. However, the efficacy of chemotherapeutic drugs is limited by the occurrence of chemotherapeutic resistance, toxicity to normal cells, poor pharmacokinetic performance, and drug delivery failure. The delivery of chemotherapy drugs to the bone to treat OS may fail for a variety of reasons, such as a lack of selectivity for OS cells, initial sudden release, short-term release, and the presence of biological barriers (such as the blood-bone marrow barrier). Nanomaterials are new materials with at least one dimension on the nanometer scale (1-100 nm) in three-dimensional space. These materials have the ability to penetrate biological barriers and can accumulate preferentially in tumor cells. Studies have shown that the effective combination of nanomaterials and traditional chemotherapy can significantly improve the therapeutic effect. Therefore, this article reviews the latest research progress on the use of nanomaterials in OS chemotherapy.
骨肉瘤（OS）是一种常见的恶性骨肿瘤，主要发生在儿童和青少年中。目前，化疗后手术或术后辅助化疗是主要的治疗方案。然而，化疗药物的疗效受到化疗耐药性的发生、对正常细胞的毒性、差的药代动力学性能和药物输送失败的限制。化疗药物输送到骨骼以治疗 OS 可能会由于多种原因而失败，例如对 OS 细胞缺乏选择性、初始突释、短期释放和存在生物屏障（如血骨髓屏障）。纳米材料是三维空间中至少有一个维度在纳米尺度（1-100nm）的新材料。这些材料具有穿透生物屏障的能力，并能优先在肿瘤细胞中积聚。研究表明，纳米材料与传统化疗的有效结合可以显著提高治疗效果。因此，本文综述了纳米材料在骨肉瘤化疗中的最新研究进展。
